Facing tough markets, Freeline Therapeutics drops Fabry disease gene therapy and lays off 30% of workforce
In an effort to improve its cash runway, the UK biotech company Freeline Therapeutics has paused the development of a gene therapy candidate for the rare metabolic condition Fabry disease. Instead, the company will refocus its efforts on a gene therapy for a different metabolic condition called Gaucher disease.
Freeline Fabry Michael Parini Eli Lilly Drug Administration Freeline Therapeutics Sangamo Therapeutic
Source: biopharma-reporter.com